At COMPUTEX 2025, ASUS showcased its comprehensive AI infrastructure solutions, targeting the computing needs of data centers, edge computing, and a wide range of intelligent applications. With a robust product portfolio, ASUS brings to life the NVIDIA AI Factory vision, illustrating how AI will be deeply embedded into enterprise IT infrastructure. This evolution continues to drive forward applications and services that shape the future of AI and high-performance computing

Linxens, a global leader in component-based solutions for authentication and traceability, and Dracula Technologies, a pioneer in ambient light energy harvesting, have announced a strategic collaboration to develop next-generation autonomous IoT solutions for traceability and smart labelling applications. This collaboration paves the way for smarter and more sustainable connected devices

Technology news, product launches and show highlights from the event attendees available for download (PDF).

As artificial intelligence (AI) and semiconductors become central to the intensifying U.S.–China tech rivalry, and rare earth resource challenges elevate their strategic importance, the Office of National Assembly Member Song Seok-jun will host a high-level seminar titled "Global AI and Semiconductor Cooperation Strategy" on November 10, 2025 (Monday), from 9:30 AM to 11:30 AM at the National Assembly Library Grand Auditorium.The seminar will be co-hosted by Mr. Colley Hwang, Chairman of Taiwan's DIGITIMES Group, and Professor Sung Soo Eric Kim, Founder of Datacrunch Global, Adjunct Professor at Yonsei University Graduate School of Business, and Visiting Professor of AI Strategy at National Taiwan University.DIGITIMES is the world's largest semiconductor-focused media and research institution, co-founded by Morris Chang (Founder of TSMC) and Stan Shih (Founder of Acer). Chairman Colley Hwang is a globally recognized semiconductor strategist who has advised CEOs of leading ICT companies worldwide.Professor Eric Kim is a renowned authority in global AI strategy and a key figure in building semiconductor and AI cooperation networks across Korea, the United States, Japan, and Taiwan.This seminar marks a significant diplomatic and strategic occasion, with Taiwan's Ministry of Foreign Affairs dispatching an official envoy to participate. The event is expected to convene 300 attendees from government, industry, and academia to explore new pathways for international collaboration in emerging technologies.The event will take place on Monday, November 10, 2025, from 9:30 AM to 11:30 AM at the Grand Auditorium of the National Assembly Library, which accommodates up to 300 attendees. Registration is available via Google Form. For inquiries, please contact Professor Sung Soo (Eric) Kim.Korean National Assembly to Host Global AI and Semiconductor Cooperation Strategy Seminar. Credit: DIGITIMES

Dr. Ali Okhowat, a Canadian physician with a background spanning humanitarian work in conflict zones to co-founding the World Health Organization (WHO) Innovation Hub, is now using artificial intelligence to solve one of healthcare’s most persistent problems: administrative burden. Through his company Aya Health Technologies Inc., he has developed an AI scribe solution called "Autochart.ai Health Assistant". The team joins the Canadian Technology Accelerator for startups in the second half of 2025, leveraging Taiwan’s proactive push toward "smart hospitals" to enter Asian markets.Describing himself as "a physician by training, but a geek at heart," Dr. Okhowat's career trajectory is unique. After completing training in Canada, he worked with the International Committee of the Red Cross in low-resource and conflict areas, including Gaza and Afghanistan, followed by a post with the WHO overseeing the Middle East and North Africa. This field experience heavily influenced his belief in using technology to make care more accessible and efficient, eventually leading him to co-found the WHO Innovation Hub in Geneva.The Genesis of Autochart.ai Health AssistantThe concept for Autochart.ai was born from the direct experience of a practicing physician. Following his return to Canada and involvement in the COVID-19 response, Dr. Okhowat co-established a medical clinic in British Columbia intended to function as an innovation lab for digital health solutions.The resulting product, Autochart.ai, is an AI health assistant and clinical workflow solution designed to reduce the time health providers spend on documentation."The first part is that a note has to be generated documenting what actually happened and what the next steps were," Dr. Okhowat explained. "We are trying to help all health providers who are somewhat burdened with this task of having to create that initial clinical document, and then all of the downstream documents that are also needed, things like referral notes, patient communications messages."The solution, which is built on the Microsoft Azure Foundry and leverages various Large Language Models (LLMs), has been fully commercialized since November 2024 and is currently being used by subscribers in Canada and the US, including several British Columbia providers and health facilities involved in a provincial AI Scribe pilot program.A Focus on Multilingual ContextA key differentiator for Autochart.ai is its robust support for diverse linguistic environments. Recognizing the need for global utility, the company prioritized multilingual capability from the start."We translated the public-facing website fully into 10 different languages, and the interface into 13 different languages," Dr. Okhowat stated. "The number of languages that we accept in terms of input languages and output languages are over 100 different languages and dialects," including support for both simplified and traditional Chinese text. This focus aims to address not only single-language needs but also multilingual, multi-issue, and multi-patient encounters common in clinical settings. The software can also integrate visual context, such as analyzing images of dermatologic lesions, into the generated documentation.Scaling in Taiwan's Smart Hospital EcosystemDr. Okhowat's visit to Taiwan for the Startup Acceleration Program is timely, aligning with the government’s recent initiative to encourage hospitals to transform into "smart hospitals" by digital transformation, robotics, and AI.In response to Taiwan’s changing demographics and rising healthcare needs, the government has just launched the "Healthy Taiwan Deep Cultivation Plan" (2025–2029) in April with a total budget of NT$48.9 billion (US$1.63 billion), focusing on four key areas-better working conditions for medical staff, diverse talent cultivation, smart healthcare technology, and sustainable, socially responsible medicine-to advance tiered care, workforce retention, and healthcare system reform.  Autochart.ai's strategy for entering the market centers on three pillars:1. Localization and Integration: Finding local partners to customize the solution and integrate it with Taiwan’s established Electronic Medical Records (EMRs) and world-class hardware manufacturers.2. Regulatory Adherence: Gaining a deep understanding of local data security and Taiwan FDA health pathway regulations to ensure full compliance. The system is already designed to support on-premise or local secure cloud environments to meet strict data privacy demands.3. Investment Synergy: Engaging with the local investor community to secure funding necessary for scaling the solution, with the goal of making it a "homegrown solution in Taiwan."The company offers flexible business models, including Software as a Service (SaaS), API-based integration, and licensing. Dr. Okhowat noted the potential for innovative monetization, moving toward a value-aligned model such as a per-chart fee with a managed upper cap to reduce costs for health systems.Future Vision: AI as a Total Health AssistantLooking ahead five years, the vision for Autochart.ai Health Assistant expands beyond supporting providers to directly empowering patients."We want to be able to help the patients just as much," Dr. Okhowat said. The company is currently developing a patient-facing AI scribe, voice agents, and physical AI implementations that would help individuals own and manage their medical records, make appointments, and summarize complex medical discussions for loved ones and their "circle of care." This evolution aims to transform the system into a comprehensive AI health assistant for all stakeholders, from providers to patients to health systems.Dr. Ali Okhowat

Ted Jin, founder and CEO of AuX Labs, is leading a charge in the food technology space with a mission driven by global impact and climate concerns. His company, which began operating around 2022, is pioneering the production of recombinant casein from yeast using precision fermentation to create animal-free dairy ingredients.Jin's journey into the bio-tech world comes after a decade in consumer packaged goods at companies like Procter & Gamble and PepsiCo, and prior experience in an earlier startup. His motivation isn't a personal dietary choice like being a vegetarian or vegan; rather, it's a deep-seated belief in the urgent need to solve food system challenges to sustainably feed a projected 10 billion people. "We aren't in a position that we can expand traditional animal agriculture," he stated, citing the finite nature of land and valuable resources.Precision Fermentation: A Non-Compromise AlternativeAuX Labs is focused on developing an ingredient: a casein powder that is functionally and nutritionally identical to the animal protein. This recombinant casein is produced by genetically manipulating yeast to express the protein. The goal is to provide a diversified protein source that doesn't force consumers to compromise on taste, function, price, or nutritional value.Jin sees their product as a necessary supplementation to-not a threat to-traditional animal agriculture. The company operates on a Business-to-Business (B2B) model, supplying this casein ingredient to consumer goods companies and food formulators to create end products like cheese.1. The Problem with "Wave One": Jin notes that the first wave of alternative proteins, which focused heavily on plant-based options, is subsiding as consumers demand products that are not just novel, but also taste good, are nutritious, and are priced comparably to animal products.2. Safety and Regulation: The company already holds a self-affirmed GRAS (Generally Recognized as Safe) status in the United States, which is crucial legwork in substantiating the protein's safety for human consumption.Global Expansion: A Look to Asia and TaiwanAuX Labs' core launch markets are currently Canada and the United States. The company is venture-backed, having closed a pre-seed and currently in the process of closing a new seed round, ensuring financial stability for the "coming period".Taiwan is positioned as the company's "first test" and a potential proving ground for Asian markets. Jin believes the Taiwanese market offers the agility of local companies and a population with a positive bias towards nutrition and health consciousness. A successful launch here would give the company confidence to pursue similar approaches in adjacent markets like Northeast and Southeast Asia (including Japan, Korea, and mainland China).Challenges to Overseas SuccessScaling into new markets is not without its difficulties, which Jin identifies in two key areas:1. Operating Expertise: Mastering the logistics of manufacturing in Canada and then exporting the casein ingredient into Taiwan, subject to the appropriate regulations.2. Local Partnerships: Finding a committed local partner in Taiwan, not just for the short term but for a multi-year effort. Jin stresses that this ingredient is novel, not just to Taiwan, but "new to the world".While the immediate plan is to import the Canadian-produced casein ingredient, establishing a local manufacturing presence in Taiwan remains an option if there is strong demand. Before that, the company will also need to validate their GRAS dossier and notify or file with the Taiwanese FDA.The Ultimate Goal: Price ParityJin's ultimate aspiration for AuX Labs is to be recognized as a pioneer in recombinant proteins. While he sees technology as "mature," he admits that the pricing is not mature yet. The final goal is to bring these animal-free proteins to market at a price point that is similar to animal proteins-something the regular consumer can afford-over the next few years. Achieving this price parity will be the key to establishing yeast-derived proteins as a viable and sufficient supply source for the global food system.Ted Jin, founder and CEO of AuX Labs. Credit: AuX Labs